SEC Form 8-K filed by Vor Biopharma Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2025

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

Registrant’s telephone number, including area code: (617) 655-6580

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Appointment of Principal Financial Officer and Principal Accounting Officer

On May 19, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s principal financial officer and principal accounting officer.

Information regarding Dr. Ang’s background and business experience is set forth under the caption “Class III Directors Continuing in Office Until the 2027 Annual Meeting” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2025 (as revised by the Company’s revised proxy statement filed with the Securities Exchange Commission on April 30, 2025) and is incorporated herein by reference. There are no arrangements or understandings between Dr. Ang and any other persons pursuant to which he was selected as an officer or director of the Company. There are also no family relationships between Dr. Ang and any director or executive officer of the Company, and Dr. Ang has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

The Company did not enter into, or materially amend, any material plan, contract or arrangement to which Dr. Ang is a party or in which he participates in connection with Dr. Ang’s designation as principal financial officer and principal accounting officer, or make or modify any grant or award to Dr. Ang under any such plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.